Latest Insider Transactions at Tactile Systems Technology Inc (TCMD)
This section provides a real-time view of insider transactions for Tactile Systems Technology Inc (TCMD). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of TACTILE SYSTEMS TECHNOLOGY INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of TACTILE SYSTEMS TECHNOLOGY INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 12
2025
|
Elaine M. Birkemeyer Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,921
-2.86%
|
$26,289
$9.94 P/Share
|
|
May 08
2025
|
Sheri Louise Dodd Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,149
-1.71%
|
$28,341
$9.83 P/Share
|
|
May 08
2025
|
William W Burke Director |
SELL
Open market or private sale
|
Direct |
3,300
-6.37%
|
$29,700
$9.67 P/Share
|
|
May 07
2025
|
Boyd Vindell Washington Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,078
+31.33%
|
-
|
|
May 07
2025
|
Carmen B Volkart Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,078
+29.9%
|
-
|
|
May 07
2025
|
David Brent Shafer Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,078
+24.77%
|
-
|
|
May 07
2025
|
Laura G. King Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,078
+45.77%
|
-
|
|
May 07
2025
|
Raymond Huggenberger Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,078
+22.21%
|
-
|
|
May 07
2025
|
Valerie L. Asbury Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,078
+24.77%
|
-
|
|
May 07
2025
|
William W Burke Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,078
+23.68%
|
-
|
|
Mar 11
2025
|
Daniel L. Reuvers Director |
BUY
Bona fide gift
|
Indirect |
68,162
+50.0%
|
-
|
|
Mar 11
2025
|
Daniel L. Reuvers Director |
SELL
Bona fide gift
|
Direct |
68,162
-31.76%
|
-
|
|
Feb 25
2025
|
Daniel L. Reuvers Director |
SELL
Open market or private sale
|
Direct |
28,338
-11.66%
|
$396,732
$14.18 P/Share
|
|
Feb 25
2025
|
Kristie Burns Sr. VP Mktg & Clinical Affairs |
SELL
Open market or private sale
|
Direct |
6,468
-7.7%
|
$90,552
$14.4 P/Share
|
|
Feb 25
2025
|
Elaine M. Birkemeyer Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,066
-1.98%
|
$28,924
$14.51 P/Share
|
|
Feb 24
2025
|
Elaine M. Birkemeyer Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,778
-3.5%
|
$52,892
$14.7 P/Share
|
|
Feb 24
2025
|
Kristie Burns Sr. VP Mktg & Clinical Affairs |
SELL
Open market or private sale
|
Direct |
4,830
-5.44%
|
$67,620
$14.65 P/Share
|
|
Feb 24
2025
|
Daniel L. Reuvers Director |
SELL
Open market or private sale
|
Direct |
10,938
-4.31%
|
$153,132
$14.55 P/Share
|
|
Feb 20
2025
|
Sheri Louise Dodd Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
85,777
+20.37%
|
-
|
|
Feb 20
2025
|
Laura G. King Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,970
+50.0%
|
-
|
|
Feb 20
2025
|
Elaine M. Birkemeyer Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46,581
+12.99%
|
-
|
|
Feb 20
2025
|
Kristie Burns Sr. VP Mktg & Clinical Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
24,069
+8.61%
|
-
|
|
Feb 20
2025
|
Daniel L. Reuvers Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,853
+5.88%
|
-
|
|
Aug 12
2024
|
Sherri Lee Ferstler Senior VP, Sales |
SELL
Open market or private sale
|
Direct |
1,550
-3.84%
|
$20,150
$13.07 P/Share
|
|
Aug 07
2024
|
Sheri Louise Dodd Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
64,959
+39.71%
|
-
|
|
May 16
2024
|
Elaine M. Birkemeyer Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,041
-4.73%
|
$39,533
$13.68 P/Share
|
|
May 08
2024
|
William W Burke Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,469
+22.65%
|
-
|
|
May 08
2024
|
William W Burke Director |
SELL
Open market or private sale
|
Direct |
2,500
-9.0%
|
$35,000
$14.06 P/Share
|
|
May 08
2024
|
Boyd Vindell Washington Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,469
+35.32%
|
-
|
|
May 08
2024
|
Carmen B Volkart Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,469
+32.62%
|
-
|
|
May 08
2024
|
David Brent Shafer Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,469
+24.23%
|
-
|
|
May 08
2024
|
Raymond Huggenberger Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,469
+20.64%
|
-
|
|
May 08
2024
|
Sheri Louise Dodd Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,469
+23.73%
|
-
|
|
May 08
2024
|
Valerie L. Asbury Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,469
+24.23%
|
-
|
|
May 06
2024
|
Kristie Burns Sr. VP Mktg & Clinical Affairs |
SELL
Open market or private sale
|
Direct |
815
-1.29%
|
$11,410
$14.37 P/Share
|
|
Feb 29
2024
|
Kristie Burns Sr. VP Mktg & Clinical Affairs |
SELL
Open market or private sale
|
Direct |
243
-0.38%
|
$3,645
$15.25 P/Share
|
|
Feb 29
2024
|
Daniel L. Reuvers Director |
SELL
Open market or private sale
|
Direct |
1,396
-0.58%
|
$20,940
$15.25 P/Share
|
|
Feb 27
2024
|
Kristie Burns Sr. VP Mktg & Clinical Affairs |
SELL
Open market or private sale
|
Direct |
1,091
-1.69%
|
$16,365
$15.58 P/Share
|
|
Feb 27
2024
|
Daniel L. Reuvers Director |
SELL
Open market or private sale
|
Direct |
4,689
-1.92%
|
$70,335
$15.6 P/Share
|
|
Feb 26
2024
|
Kristie Burns Sr. VP Mktg & Clinical Affairs |
SELL
Open market or private sale
|
Direct |
2,015
-3.08%
|
$30,225
$15.9 P/Share
|
|
Feb 26
2024
|
Daniel L. Reuvers Director |
SELL
Open market or private sale
|
Direct |
6,239
-2.49%
|
$93,585
$15.81 P/Share
|
|
Feb 24
2024
|
Elaine M. Birkemeyer Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,848
+4.24%
|
-
|
|
Feb 24
2024
|
Kristie Burns Sr. VP Mktg & Clinical Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
11,762
+8.3%
|
-
|
|
Feb 24
2024
|
Daniel L. Reuvers Director |
BUY
Grant, award, or other acquisition
|
Direct |
58,030
+10.45%
|
-
|
|
Feb 23
2024
|
Kristie Burns Sr. VP Mktg & Clinical Affairs |
SELL
Open market or private sale
|
Direct |
2,249
-4.02%
|
$31,486
$14.8 P/Share
|
|
Feb 23
2024
|
Daniel L. Reuvers Director |
SELL
Open market or private sale
|
Direct |
5,378
-2.72%
|
$75,292
$14.85 P/Share
|
|
Feb 21
2024
|
Kristie Burns Sr. VP Mktg & Clinical Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
19,452
+25.78%
|
-
|
|
Feb 21
2024
|
Daniel L. Reuvers Director |
BUY
Grant, award, or other acquisition
|
Direct |
72,046
+26.71%
|
-
|
|
Feb 21
2024
|
Elaine M. Birkemeyer Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,420
+34.52%
|
-
|
|
Feb 21
2024
|
Sherri Lee Ferstler Senior VP, Sales |
BUY
Grant, award, or other acquisition
|
Direct |
21,613
+34.9%
|
-
|